Table 3.
The predictive values of related clinical features and risk score
| Variables | PatientN = 317 | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Race | |||||
| Asian | 151 | 1 (reference) | |||
| Black | 14 | 1.890 (0.746‐4.793) | .180 | ||
| White | 141 | 1.138 (0.757‐1.710) | .535 | ||
| Gender | |||||
| Female | 99 | 1 (reference) | 1 (reference) | ||
| Male | 217 | 0.657 (0.445‐0.969) | .034 a | 1.354 (0.698‐2.626) | .370 |
| Age | |||||
| <=55 | 119 | 1 (reference) | |||
| >55 | 197 | 1.102 (0.739‐1.644) | .634 | ||
| TNM stage | |||||
| I | 154 | 1 (reference) | 1 (reference) | ||
| II | 77 | 1.339 (0.799‐2.244) | .268 | 1.636 (0.802‐3.338) | .176 |
| III | 80 | 2.592 (1.668‐4.028) | <.001 a | 2.714 (1.467‐5.019) | .001 a |
| IV | 5 | 5.499 (1.689‐17.901) | .005 a | ||
| T stage | |||||
| T1 | 156 | 1 (reference) | 1 (reference) | ||
| T2 | 79 | 1.294 (0.774‐2.163) | .325 | 0.000 (0.000‐1.640E58) | .908 |
| T3 | 71 | 2.461 (1.565‐3.869) | <.001 a | 0.448 (0.051‐3.955) | .470 |
| T4 | 10 | 5.040 (2.231‐11.384) | <.001 a | 0.617 (0.061‐6.210) | .682 |
| N stage | |||||
| N0 | 243 | 1 (reference) | |||
| N1 | 1 | 0.049 (0.000‐4.654E32) | .940 | ||
| M stage | |||||
| M0 | 248 | 1 (reference) | |||
| M1 | 4 | 3.960 (1.243‐12.617) | .020 a | ||
| Radiation therapy | |||||
| No | 288 | 1 (reference) | |||
| Yes | 8 | 1.074 (0.340‐3.397) | .903 | ||
| Neoplasm cancer | |||||
| Tumor free | 174 | 1 (reference) | 1 (reference) | ||
| With tumor | 126 | 2.498 (1.643‐3.798) | <.001 a | 2.432 (1.386‐4.267) | .002 a |
| Residual tumor | |||||
| R0 | 280 | 1 (reference) | |||
| R1 + R2 | 11 | 1.038 (0.328‐3.284) | .949 | ||
| Fibrosis ishak score | |||||
| No fibrosis | 62 | 1 (reference) | |||
| Portal fibrosis | 28 | 0.861 (0.365‐2.035) | .734 | ||
| Fibrous speta | 24 | 0.896 (0.362‐2.219) | .813 | ||
| Nodular formation and incomplete cirrhosis | 8 | 0.841 (0.196‐3.603) | .816 | ||
| Established cirrhosis | 57 | 0.807 (0.420‐1.552) | .521 | ||
| BMI | |||||
| <18.5 | 18 | 0.485 (0.188‐1.250) | .134 | 0.439 (0.138‐1.396) | .163 |
| 18.5‐23.9 | 128 | 1 (reference) | 1 (reference) | ||
| 24‐27.9 | 70 | 0.505 (0.297‐0.856) | .011 a | 0.543 (0.279‐1.056) | .072 |
| ≥28 | 74 | 0.611 (0.369‐1.012) | .056 | 0.346 (0.159‐0.754) | .008 a |
| Histologic grade | |||||
| G1 | 41 | 1 (reference) | |||
| G2 | 150 | 1.144 (0.608‐2.155) | .677 | ||
| G3 | 112 | 1.293 (0.678‐2.469) | .436 | ||
| G4 | 12 | 1.770 (0.620‐5.053) | .286 | ||
| Platelet result | |||||
| <100 × 10^9 | 15 | 2.061 (0.924‐4.599) | .077 | ||
| 100‐300 × 10^9 | 200 | 1 (reference) | |||
| >300 × 10^9 | 44 | 1.674 (0.990‐2.829) | .054 | ||
| Family cancer history | |||||
| No | 185 | 1 (reference) | |||
| Yes | 92 | 1.150 (0.767‐1.725) | .500 | ||
| Vascular tumor cell type | |||||
| None | 178 | 1 (reference) | |||
| Micro | 76 | 1.019 (0.602‐1.725) | .944 | ||
| Macro | 14 | 2.067 (0.933‐4.582) | .074 | ||
| Hist hepato carc fact | |||||
| No history of primary risk factors | 86 | 1 (reference) | 1 (reference) | ||
| Alcohol consumption | 95 | 0.649 (0.399‐1.056) | .082 | 0.605 (0.299‐1.223) | .162 |
| Hepatitis b | 76 | 0.373 (0.208‐0.671) | .001 a | 0.461 (0.214‐0.996) | .049 a |
| Hepatitis c | 29 | 0.876 (0.435‐1.764) | .712 | 0.389 (0.127‐2.626) | .098 |
| Risk score | |||||
| Low | 159 | 1 (reference) | 1 (reference) | ||
| High | 157 | 1.802 (1.224‐2.652) | .003 a | 2.997 (1.634‐5.497) | <.001 a |
HR, hazard ratio; CI, confidence interval; BMI, Body Mass Index; Hist hepato carc fact, history of Hepatocellular Carcinoma risk factors.
Bold font represents a statistically significant p‐value.
a
P < .05.